Cyclophosphamide mitigates non-ICANS neurotoxicities after ciltacabtagene autoleucel treatment

Potentially fatal non-ICANS neurotoxicities (NINTs) following BCMA-targeted CAR T-cell therapy have been linked to high CAR T-cell expansion and prolonged persistence. Cyclophosphamide in an effort to ablate CAR T-cells is an effective treatment strategy to mitigate steroid-refractory courses of NINTs.